Clal Biotechnology (Israel) Investor Sentiment

CBI Stock   35.20  0.20  0.57%   
About 54% of Clal Biotechnology's investor base is interested to short. The analysis of current outlook of investing in Clal Biotechnology Industries suggests that many traders are impartial regarding Clal Biotechnology's prospects. The current market sentiment, together with Clal Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use Clal Biotechnology stock news signals to limit their universe of possible portfolio assets.
  
over three months ago at news.google.com         
Clal Biotechnology Industries Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - ...
Google News at Macroaxis
over six months ago at news.google.com         
Retail investors who hold 45 percent of Elicio Therapeutics, Inc. gained 14, insiders profited as we...
Google News at Macroaxis
over six months ago at news.google.com         
Clal Biotechnology Industries Full Year 2023 Earnings 0.20 loss per share - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Blue Cross NCs Blue Premier program saved 164M in 2022 - FierceHealthcare
Google News at Macroaxis
over a year ago at news.google.com         
China Castson 81 Finance to Swing to Profit in H1 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Price transparency proposal leaves room for improvement, experts say - FierceHealthcare
Google News at Macroaxis
over a year ago at news.google.com         
Clal Biotech co makes progress on cancer immunotherapy - Globes
Google News at Macroaxis
over a year ago at news.google.com         
TD Cowen Maintains REE Automotive Ltd - Outperform ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Earnings Flash HEALTHIER CHOICES MANAGEMENT ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
The Market Doesnt Like What It Sees From Clal Biotechnology Industries Ltd.s Revenues Yet - Simply W...
Google News at Macroaxis
over a year ago at news.google.com         
Israeli cyberattack co Quadream to close - Globes - Globes
Google News at Macroaxis
over a year ago at news.google.com         
Geffen Residence Renewal Reports Full Year 2022 Earnings - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Mark Cuban-Backed Startup Delivers Charging To EVs Just Like ... - Investing.com UK
Google News at Macroaxis
over a year ago at news.google.com         
Elbit Systems Ltd. Shares Bought by Credit Suisse ... - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
HC Wainwright Assesses Genmab AFirst-Quarter Ss 2023 Earnings ... - Best Stocks
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Clal Biotechnology that are available to investors today. That information is available publicly through Clal media outlets and privately through word of mouth or via Clal internal channels. However, regardless of the origin, that massive amount of Clal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Clal Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Clal Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Clal Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Clal Biotechnology alpha.

Clal Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Clal Stock analysis

When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges